Evidence map›Paper›PMID 34069422›Full record

ReviewAntioxidants (Basel, Switzerland)2021

MicroRNAs and Oxidative Stress: An Intriguing Crosstalk to Be Exploited in the Management of Type 2 Diabetes.

Teresa Vezza, Aranzazu M de Marañón, Francisco Canet, Pedro Díaz-Pozo, Miguel Marti, Pilar D'Ocon, Nadezda Apostolova, Milagros Rocha, Víctor M Víctor

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Antioxidant Intervention Against Microplastic Hazards.Antioxidants (Basel, Switzerland) · 2025
    Review
  7. Review
  8. Review
  9. Identification of Antioxidant Methyl Derivatives ofInternational journal of molecular sciences · 2024
    Article
  10. Oxidative Stress, Endothelial Dysfunction, andAntioxidants & redox signaling · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Teresa VezzaService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain.
Aranzazu M de MarañónService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain.ORCID 0000-0002-4153-0396
Francisco CanetService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain.ORCID 0000-0002-6626-2762
Pedro Díaz-PozoService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain.
Miguel MartiDepartment of Pharmacology, University of Valencia, 46010 Valencia, Spain.
Pilar D'OconDepartment of Pharmacology, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0001-8544-7124
Nadezda ApostolovaDepartment of Pharmacology, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0002-4487-2471
Milagros RochaService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain.ORCID 0000-0003-2923-6546
Víctor M VíctorService of Endocrinology and Nutrition, University Hospital Doctor Peset, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), 46017 Valencia, Spain.ORCID 0000-0002-3027-3945
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESUniversitat de València · ES

Funding

Carlos III Health Institute PI18/00932Carlos III Health Institute PI19/00838Carlos III Health Institute PI19/0437FISABIO UGP-15-220Ministry of Education of the Valencian Regional Government PROMETEO/2019/027
6 · The paper itself

Abstract

Type 2 diabetes is a chronic disease widespread throughout the world, with significant human, social, and economic costs. Its multifactorial etiology leads to persistent hyperglycemia, impaired carbohydrate and fat metabolism, chronic inflammation, and defects in insulin secretion or insulin action, or both. Emerging evidence reveals that oxidative stress has a critical role in the development of type 2 diabetes. Overproduction of reactive oxygen species can promote an imbalance between the production and neutralization of antioxidant defence systems, thus favoring lipid accumulation, cellular stress, and the activation of cytosolic signaling pathways, and inducing β-cell dysfunction, insulin resistance, and tissue inflammation. Over the last few years, microRNAs (miRNAs) have attracted growing attention as important mediators of diverse aspects of oxidative stress. These small endogenous non-coding RNAs of 19-24 nucleotides act as negative regulators of gene expression, including the modulation of redox signaling pathways. The present review aims to provide an overview of the current knowledge concerning the molecular crosstalk that takes place between oxidative stress and microRNAs in the physiopathology of type 2 diabetes, with a special emphasis on its potential as a therapeutic target.

Indexed as

microRNAoxidative stressredox signalingtype 2 diabetes

Identifiers

PMID34069422
PMCPMC8159096
OpenAlexW3160473479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.